Difference between revisions of "Adebrelimab (SHR-1316)"
Jump to navigation
Jump to search
m |
m |
||
Line 1: | Line 1: | ||
+ | ==Mechanism of action== | ||
+ | *From the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/adebrelimab NCI Drug Dictionary]: An immunoglobulin G4 (IgG4), humanized monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, adebrelimab specifically targets and binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1). This reverses T-cell inactivation caused by PD-1/PD-L1 signaling and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. | ||
==Also known as== | ==Also known as== | ||
− | *'''Code | + | *'''Code names:''' HTI-1088, SHR-1316 |
[[Category:Drugs]] | [[Category:Drugs]] |
Latest revision as of 23:45, 31 July 2023
Mechanism of action
- From the NCI Drug Dictionary: An immunoglobulin G4 (IgG4), humanized monoclonal antibody directed against the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, adebrelimab specifically targets and binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1). This reverses T-cell inactivation caused by PD-1/PD-L1 signaling and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells.
Also known as
- Code names: HTI-1088, SHR-1316